Ashkan M. Abbey, MD, presented 1-year fellow eye substudy results for ABBV-RGX-314, a subretinal gene therapy from Regenxbio for wet age-related macular degeneration. At Clinical Trials at the Summit, ...

and neovascular age-related macular degeneration (wet-AMD). The data were presented at the MaculArt Meeting, June 29 – July 1, 2025 in Paris. MGB represents a potential alternative to current standard ...

Age-Related Macular Degeneration Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035 The r ...

Through the program, gene therapies are developed to treat patients with retinitis pigmentosa caused by pathogenic variants ...

A combination of genetics and drinking instant coffee is linked to an increased risk of developing a common form of ...

Our eyes are one of the most important organs of our body, and not only are they our tool to see the outside world, but they can also be a reflection of our health. Changes in our eyes are not always ...